Kornimate/medical-research-clean huggingface dataset:
targeting methods of botulinum toxin injections for cervical dystonia

Conditions: Idiopathic Cervical Dystonia

Summary: botulinum toxin injections are the treatment of choice for cervical dystonia. even if this treatment is successful for most of the patients, partials or completes failures still remained. usually, botulinum toxin injections are realized by clinical localization techniques (observation and palpation of target muscles). the use of ultrasonography to guide injections of botulinum toxin has theoretical benefits (as an improved precision, an improved reproducibility, the targeting of deep-seated muscles, and a lower risk of adverse events) but its interest has never been demonstrated.

open label non-randomised controlled clinical trial comparing clinical localization techniques and ultrasonography to guide injections of botulinum toxin a. the primary outcome is to compare both techniques of injection regarding to the health impact of cervical dystonia (cdip-58) measured 1 month after injection. the results of this clinical trial will help the clinician to decide which strategy of injection is the most effective in terms of benefit/risk ratio to treat the cervical dystonia.

Eligibility criteria:
inclusion criteria: * patient older than 18 years old * focal idiopathic cervical dystonia treated by injections of botulinum toxin type a (onabotulinumtoxina, botox® ; abobotulinumtoxina, dysport® ; or incobotulinumtoxina, xeomin®). * patient who have previously received at least 3 cycles of botulinum toxin a injections in this specific indication * injections realized with clinical targeting exclusively or ultrasonography targeting exclusively * patient who is not opposed to its participation in this study * patient affiliated to the sécurité sociale * patient able to comply with study procedures and study duration exclusion criteria: * woman pregnant, woman of childbearing age not taking effective contraception or breastfeeding * contraindication of botulinum toxin injections as : * hypersensivity to the botulinum toxin a or to an excipient of the commercialized treatment (onabotulinumtoxina, botox® ; abobotulinumtoxina, dysport® ; incobotulinumtoxina, xeomin®) * generalized muscular activity disorder (myasthenia gravis, lambert-eaton syndrome) * infection or inflammation of the injection site * concomitant treatment that can interact with botulinum toxin a or modify the function of the neuromuscular synapse junction (anticholinergics, curare and other myorelaxing agents, aminoglycosides, amino-4-quinolines) * documented resistance to the botulinum toxin a * inability to receive the information, inability to participate to the all study duration, refusal to sign the consent * emg-guided botulinum toxin injections

Keywords: cervical dystonia botulinum toxin ultrasound-guided injection cdip58 twstrs-2
design and implementation of a drunk driving detection system

Conditions: Transportation Accidents; Drunk Driving; Alcohol Drinking; Impaired Driving

Summary: to analyse driving behavior of individuals under the influence of alcohol using a validated research driving simulator. based on the driving variables provided by the simulator the investigators aim at establishing algorithms capable of discriminating sober and drunk driving patterns using machine learning neural networks (deep machine learning classifiers).

driving under the influence of alcohol (or "drunk driving") is one of the most significant causes of traffic accidents. alcohol consumption impairs neurocognitive and psychomotor function and has been shown to be associated with an increased risk of driving accidents. automotive technology is highly dynamic, and fully autonomous driving might, in the end, resolve the issue of alcohol impaired accidents. however, autonomous driving (level 4 or 5) is likely to be broadly available only to a substantially later time point than previously thought due to increasing concerns of safety associated with this technology. therefore, solutions bridging the upcoming period by more rapidly and directly addressing the problem of drunk driving-associated traffic incidents are urgently needed. on the supposition that driving behaviour differs significantly between sober and drunk states, the investigators assume that different driving patterns in both states can be used to generate drunk driving detection models using machine learning neural networks (deep machine learning classifiers).

Eligibility criteria:
inclusion criteria: * informed consent as documented by signature. * in possession of a swiss or eu driving license for at least two years. * at least driving 1'000 kilometers per year. * no special equipment needed when driving. * drinks alcohol at least occasionally (moderate/social consumption). * fluent in (swiss) german and no speech impairment. * lives in or near bern. exclusion criteria: * health concerns that are incompatible with alcohol consumption. * any potential participant currently taking illegal drugs or medications that interact with alcohol. * women who are pregnant or breast feeding. * intention to become pregnant during the course of the study. * teetotallers (alcohol abstinent persons). * alcohol misuse (excessive alcohol consumption habits/risky drinking behaviour (according to who definition) and/or peth in capillary blood \> 210 ng/ml at first visit. * known or suspected non-compliance or drug abuse. * inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the participant. * participation in another study with investigational drug within the 30 days preceding and during the present study.

Keywords: metabolism machine learning automotive technology driving driving simulator alcohol biomarker cortisol phosphatidylethanol
early-stage ovarian clear cell carcinoma (occc) patients at risk of recurrence

Conditions: FIGO Stage IC2 to II Ovarian Clear Cell Carcinoma

Summary: the goal of this observational study is to determine the risk of recurrence in early-stage occc (ovarian clear cell carcinoma) patients who received postoperative adjuvant treatment. participants were received platinum-based adjuvant therapy following debulking surgery will be included for the study.

this is a retrospective, global multicenter, single-arm, study for early-stage occc (ovarian clear cell carcinoma) patients at risk of recurrence following the first-line treatment. this study is planned to enroll 272 patients eligible for participation from two study sites in taiwan, one in korea, and one in japan. the study will use archival formalin-fixed paraffin-embedded (ffpe) samples from patients who have received adjuvant therapy following debulking surgery. the study is designed to identify occc patients at risk for relapse and apply clinical stratification by ihc staining of 3 selected markers (cd45, cd8, tryptase) to prepare as clinical assays.

Eligibility criteria:
inclusion criteria: * women aged ≥20 years old. * participant with histologically confirmed occc of stage ic2, ic3, iia and iib by international federation of gynecology and obstetrics (figo) 2014 system. * participant has received platinum-based regimens for 3 to 6 cycles combined with paclitaxel, gemcitabine, cyclophosphamide, or bevacizumab adjuvant therapy following debulking surgery. * formalin-fixed paraffin-embedded (ffpe) tissue samples available. exclusion criteria: * absence of histological confirmation of the diagnosis. * unusable sample or biologically deteriorated.
expression of the inhibitory receptors on lymphocytes t cells after lung cancer surgery.

Conditions: Lung Cancer; Surgery

Summary: postoperative pneumonia is one of the most common complications after lung cancer surgery and associated with a morbidity and mortality. postoperative lymphopenia has been recently identified as one of risk factors for postoperative pneumonia. according to recent studies in polytrauma, cancer or septic shock, t cells dysfunction may be related to high expression of inhibitory receptors on lymphocytes.

this study will investigate prospectively tim-3, pd-1 and ctla4 expression on lymphocytes t cells before and after lung cancer surgery. patients ≥ 18 years with no history of immunosuppressive state will be included.

Eligibility criteria:
inclusion criteria: * patient ≥ 18 years undergoing lung cancer surgery by thoracoscopy exclusion criteria: * patient under guardianship/curatorship * patient who received of radiotherapy or chemotherapy in the last 6 months * patient under immunosuppressive treatment or dose of corticoids over 10 mg/day prednisolone or equivalent * patient with history of malignant blood disease or auto-immune disease * patient suffering from hiv infection and * patients with pre-operative infection * patient with an empiric antibiotic therapy introduced at operating room

Keywords: lymphopenia lung cancer surgery tim-3 pd-1 ctla-4 lymphocytes cd4 cd8
effects of a nursing-led communication using mobile health information in breast cancer patients undergoing concurrent chemotherapy

Conditions: Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Summary: breast cancer is the most common malignant tumor among women. side effects from initial chemotherapy include sleep disorders, anxiety, depression, and reduced quality of life. mental health distress is also a major issue in cancer care. this study integrates mobile health information with a nurse-led communication support plan, aiming to improve patients' physical and mental outcomes during chemotherapy.

the objective of this study is to explore the effects of a nursing-led communication support program using mobile health information on physical and mental state in breast cancer patients undergoing initial chemotherapy.

Eligibility criteria:
inclusion criteria: breast cancer initial chemotherapy exclusion criteria: patients whose cancer has recurred without undergoing the first course of chemotherapy

Keywords: breast cancer chemotherapy
the role of food sensitivity in psoriasis

Conditions: Psoriasis

Summary: psoriasis is a common chronic skin disorder that affects over 4 million people. there is no cure for psoriasis and treatment is directed at controlling patients' symptoms. the purpose of this study is to determine whether psoriasis patients are more likely to have food sensitivities than those patients without psoriasis. we will also determine if eliminating certain foods from the diet results in a change in psoriasis symptoms.

purpose: to determine the role of food sensitivity in psoriasis and assess the clinical response of an individualized elimination diet on psoriasis. design: up to 50 volunteers with psoriasis and 20 age- and sex-matched controls will be recruited for a 12-week prospective correlational study. methods: venous blood samples for the detection of antibodies against food antigens will be collected and individualized elimination diets will be designed based on the most reactive food antigens. assessments: clinical assessments of objective and subjective parameters will be measured using psoriasis area and severity index (pasi), static physicians global assessment (spga), dermatology life quality index (dlqi), and itch numeric rating scale (itch nrs). objectives: the primary objectives are to determine whether psoriasis patients are more likely to have food sensitivities and assess the clinical response of a 12-week elimination diet on psoriasis.

Eligibility criteria:
inclusion criteria: * male or female subjects, 12 years of age or older. * good general health. * willingness and ability to follow the protocol. * signed informed consent form, written and witnessed. * psoriatic group only: chronic plaque psoriasis (patients must have diagnosis for at least 6 months) or guttate psoriasis involving 2 % or greater total body surface area or 2 plaques, each measuring \> 8 cm2. * psoriatic group only: psoriasis is untreated (as defined in exclusion criteria 4) or subject has been on a stable topical or systemic treatment with no dose alteration or regimen alteration for \>12 months. exclusion criteria: * history of drug-induced psoriasis or pustular psoriasis. * moderate or severe psoriasis warranting systemic immunosuppression or inpatient admission. * pregnant, lactating, history of diabetes mellitus, thyroid disease or inflammatory bowel disease. * psoriatic group only: use of biologic treatment for psoriasis within 3 months of baseline, use of systemic immunosuppressive treatment for psoriasis within 4 weeks of baseline, or use of topical treatment for psoriasis within 2 weeks.
the effect of platelet-rich fibrin matrix on skin rejuvenation

Conditions: Skin Rejuvenation; Skin Quality; Wrinkle; Nasolabial Fold

Summary: platelet-rich fibrin matrix (prfm) is made from platelets that are extracted from a patient's blood, and many plastic surgeons and dermatologists have used it to fill in wrinkles and lines on the face. both patients and doctors have observed that it gives extra volume in these areas and improves overall appearance. however, there is no research that shows how prfm affects skin quality, such as pores, spots, red areas, and texture. the aim of this study is to determine whether prfm has a role in rejuvenating facial skin.


Eligibility criteria:
inclusion criteria: * adults 18 years of age and older who had a dermatological concern, specifically, conspicuous spots, pores, rhytids, uneven texture, or red or brown discoloration, and a visia complexion analysis score greater than 10 * agreed to continue any contraceptive hormonal therapy for duration of the study * agreed to not initiate the use of hormonal therapy during the study * agreed to not undergo any facial procedures or treatments, including injections and fillers, lasers, peels, and topical therapies, during the duration of the study * agreed to adhere to a standardized skin care regimen throughout the duration of the study consisting of the use of a single cleanser and moisturizer twice a day * agreed to refrain from excessive sun exposure/tanning exclusion criteria: * history of skin/connective tissue disorders * history of immunosuppressive therapy or radiotherapy * participation in facial procedures, such as injections, lasers, peels, and dermabrasion, in the last six months * use of topical/prescription acne medications in the last three months * current smokers or prior smokers who quit fewer than 10 years ago
influence of intraoperative fluid balance on the incidence of adverse events in pediatric cardiac surgery

Conditions: Congenital Heart Disease in Children; Surgery; Fluid Overload

Summary: the intraoperative fluid balance during pediatric cardiac surgery is a very sensitive parameter given the low circulating volume and the complexity of anesthetic management but might be deleterious if inadequately managed. the hypothesis is that a highly positive intraoperative fluid balance increases the incidence of adverse events in the short and long term. a retrospective observational study including all consecutive children admitted for cardiac surgery with cardiopulmonary bypass (cpb) from 2008 to 2018 in a tertiary children's hospital will be performed. a multivariate analysis will be carried out to study the effect of the fluid balance on the incidence of adverse events.


Eligibility criteria:
inclusion criteria: * children aged 0-16 years and * cardiac surgery with cardiopulmonary bypass and * operated between 2008 and 2018 at the queen fabiola university children's hospital (tertiary children's hospital) exclusion criteria: * asa (american society of anesthesiologists) score of 5 * jehovah's witnesses * incomplete hospital record
providing personalized health and individual lifestyle enhancing solutions (prophiles) in cvd

Conditions: Cardiovascular Diseases

Summary: the objective of the proposed project is to evaluate the usability, acceptability, and adherence of a lifestyle and behavioral self-tracking and epersuasive tool aimed at improving: 1) adherence to diet/nutrition (\<1500 mg of sodium/day and less than 10% daily free sugar intake), physical activity (pa) (150 minutes of moderate pa/week), and sleep guidelines (7-8 hours of sleep/day)-- and 2) control 3% reduction in systolic bp and glucose from baseline to end of study follow-up after 2 months (exploratory objective) in a sample of 20 patients with hypertension or diabetes. the study will utilize a step-wedge design where the 20 patients will be divided into 4 wedges (5 patients in each wedge).


Eligibility criteria:
inclusion criteria: * nyu and/or bellevue patient * diagnosed with htn and pre-diabetes/diabetes * must be english speakers * ownership of a smart phone and are willing to use it to download app built in trialx which will be free for participants * must be ambulatory exclusion criteria: * are unable or unwilling to provide informed consent; * are unable to participate meaningfully in an intervention that involves self-monitoring using software available in english (e.g., due to uncorrected sight impairment, illiterate, non-english-speaking, dementia); * are pregnant, are currently trying to become pregnant, or who become pregnant during the study * are institutionalized (e.g., in a nursing home or personal care facility, or those who are incarcerated and have limited control over self-management) * have had or are planning to have bariatric surgery during the study * have a history of heart disease, kidney disease, or retinopathy (to rule-out those with long-standing, undiagnosed t2d)
the influence of upright feeding position on pulmonary and ear morbidity

Conditions: Feeding and Eating Disorders

Summary: does upright feeding position of 3 month old infants reduce respiratory and ear morbidity during the following year?

the investigators examined the influence of teaching mothers to feed infants with their head in an upright position and evaluated the infant ear and respiratory morbidity during a one-year follow-up. mothers of 88 infants born during 2011 were instructed by trained nurses at maternal-child-health clinics to feed their infants with their head in upright position (intervention group). the control group consisted of 75 mothers of infants of similar socioeconomic background who fed their infant regularly without any instructions and were followed at another maternal-child-health clinic. feeding position was evaluated at the beginning and the end of the study, and morbidity data of both groups were evaluated at every 3-month follow-up meeting. the study was part of the phd thesis of efrat danino, head nurse of pediatric department at hadassah medical organization.

Eligibility criteria:
inclusion criteria: * healthy 3 month old infants, bottle fed at least once a day, parent agreeing to participate exclusion criteria: * prematurity, need of supplemental oxygen, broncho-pulmonary dysplasia, cystic fibrosis, familial dysautonomia, cleft lip or cleft palate, any ear-throat-lung or airway congenital anomaly, congenital heart disease, any other chronic disease of childhood or malignancy

Keywords: infant feeding position respiratory ear
cardiorenal effecs of losartan in kidney transplant recipients

Conditions: Renal Transplant Failure; Cardiovascular Complication

Summary: the influence of losartan to cardiovascular and renal outcomes in patients after renal transplatation.

the benefits of cardio and nephroprotective properties of treatment with drugs blocking the renin angiotensin aldosterone system in the general population has already been shown. there are no data on the cardiac and renal effects of this type of treatment in patients after renal transplantation. therefore, the observational, case-control study was designed in a population of kidney transplant recipients. the study group consists of patients treated with antihypertensive drugs including losartan at a minimum dose of 50mg. the control group consists of patients treated with antihypertensive drugs, without the renin angiotensin aldosterone system blockade. blood pressure will be controlled in accordance with the current recommendations. the primary aim of this study is to determine whether, in renal transplant recipients with hypertension, losartan, angiotensin ii receptor antagonist improves cardiovascular and graft outcome i.e. reduces incidence of cardiovascular complications and slows progression of graft insufficiency. secondary objective is to determine whether losartan 1. delays the occurrence of cardiovascular complications, 2. slows progression of graft insufficiency, 3. is the safe drug in renal transplant recipients, 4. decrease albuminuria and other surrogate markers of graft injury or cardiovascular involvement.

Eligibility criteria:
inclusion criteria: 740 patients, either sex, either non-diabetic or diabetic who underwent the kidney transplantation and who: 1. are at least three months post-transplantation 2. have hypertension. 3. have an estimated glomerular filtration rate greater than or equal to 30 ml/min/1.73 m2 exclusion criteria: 1. pregnant or the possibility of becoming so and breast feeding. 2. angioedema from an angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) in the history. 3. serum potassium greater than 5.5 mmol/l on two or more occasions in the preceding three months. 4. graft artery stenosis (i.e. psv of more than 200 cm/s in doppler usg) 5. left ventricular dysfunction that requires an ace inhibitor or an arb 6. new immunosuppressive agent was started or previous immunosuppressant stopped in the three months prior to study entry or plan to switch immunosuppressive agents within next three months. 7. currently on four or more blood pressure pills and have an average blood pressure over three visits greater than 150/100. 8. currently on an ace-inhibitor or an arb or treatment with an ace inhibitor or arb after kidney transplantation lasted more than 3 months. 9. had an acute coronary syndrome, episode of malignant hypertension, stroke or transient ischaemic attack in the three months prior to study entry.

Keywords: angiotensin receptor blocker kidney transplant recipients albuminuria cardiovascular disease nephroprotection
effect of iv alanyl glutamine on healing of pressure ulcers in critically ill patients

Conditions: Pressure Ulcer

Summary: in this clinical trial, we will assess pressure ulcer healing rates in critically ill patients supplemented with iv alanyl-glutamine in comparison with critically ill patients not supplemented with alanyl-glutamine.

this clinical trial will include 200 egyptian critically ill patients with bed sores equal or more than grade ii selected from ward or icu at air force specialized hospital. they will be classified into 2 groups: * group i: 100 critically ill patients will be enrolled on high protein diet and receiving iv alanyl glutamine with dose 0.3 gm/kg/ day which equal 1.5 ml/kg/day of alanyl-glutamine until discharge from icu, death (with duration of 2 weeks administration). * group ii: 100 critically ill patients will be enrolled on high protein diet either enteral or parenteral but not receiving any glutamine supplementations.

Eligibility criteria:
inclusion criteria: * patients with pressure ulcers stage 2,3 or 4, non-healing admitted to air force specialized hospital for more than a week. exclusion criteria: * patients with renal impairment (gfr \</= 30) * patients who require fluid restriction \< 1 litre/day. * patients with liver cirrhosis. (child b and c) * length of stay\< 2 weeks. * patients with deep tissue infection and/or requiring debridement of necrotic or sloughy tissue. * hemodynamically unstable patients. (on high dose of cardiac supports)